一分钟看懂
这是一项关于食管鳞状细胞癌的I 期 / II 期研究，登记的药物或干预包括Paclitaxel；Irinotecan；Pembrolizumab；MK-4830；Lenvatinib；Sacituzumab tirumotecan；Antihistamine；H2 Receptor Antagonist；Acetaminophen (or equiva，当前状态为招募中。登记地点显示中国合肥、北京、厦门、新乡等城市有研究中心记录。是否仍有名额以及是否值得进一步询问，需要向研究中心确认。
药物或干预
Paclitaxel；Irinotecan；Pembrolizumab；MK-4830；Lenvatinib；Sacituzumab tirumotecan；Antihistamine；H2 Receptor Antagonist；Acetaminophen (or equivalent)；Dexamethasone (or equivalent)；Steroid Mouthwash (dexamethasone or equivalent)；Supportive care measures · I 期 / II 期
登记条件中文摘要
年龄范围：18岁及以上
登记的基本范围为不限性别，年龄18岁及以上；以下仅摘录4项专业入选条件，需结合英文原文并由研究团队确认。
登记记录列出8项主要排除条件，具体医学含义需结合英文原文并由研究团队确认。
中国哪些地方有记录
以下地点来自登记信息，不代表此刻仍有名额；请向研究中心确认最新情况。
- Anhui Provincial Hospital ( Site 3501) · 合肥
- Beijing Cancer hospital-Digestive Oncology ( Site 3500) · 北京
- The First Affiliated Hospital of Xiamen University ( Site 3516) · 厦门
- The First Affiliated Hospital of Xinxiang Medical University-Oncology ( Site 3510) · 新乡
- Henan Cancer Hospital ( Site 3518) · 郑州
- First Huai'an Hospital Affiliated to Nanjing Medical University ( Site 3506) · 淮安
- Shanghai Chest Hospital-Esophageal surgery department ( Site 3513) · 上海
- Zhejiang Cancer Hospital-Thoracic oncology ( Site 3511) · 杭州
入选条件原文摘录
以下为摘录，请打开原始登记查看完整入排标准。
- * Histologically or cytologically confirmed diagnosis of metastatic or locally advanced unresectable esophageal squamous cell carcinoma (ESCC)
- * Has experienced investigator documented radiographic or clinical disease progression on one prior line of standard therapy, that includes a platinum agent and previous exposure to an anti-programmed cell death 1 (PD1)/programmed cell death ligand 1 (PD-L1) based immune oncology (IO) therapy
- * Has provided an archival or most recent tumor tissue sample obtained as part of clinical practice
- * Participants who have adverse events (AEs) due to previous anticancer therapies must have recovered to ≤Grade 1 or baseline. Participants with endocrine-related AEs who are adequately treated with hormone replacement or participants who have ≤Grade 2 neuropathy are eligible
联系前需要确认
请继续确认中心是否启动、疾病分型、既往治疗、检查费用和知情同意安排。
查看登记信息
登记号：NCT05319730；登记信息更新于 2026-10-07；本站同步于 2026-10-08，中国中心当前名额未经人工确认。